Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
14. Oktober 2024 10:30 ET
|
Biofrontera Inc.
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim...
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
12. Oktober 2022 14:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications...
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
24. Mai 2022 11:29 ET
|
Biofrontera Inc.
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin...
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
10. Januar 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
02. Dezember 2021 09:15 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering
28. Oktober 2021 21:40 ET
|
Biofrontera Inc.
WOBURN, MA. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of...